Twenty-eight days after the administration of the different treatments, the learning and memory abilities of AD model rats in the piracetam and NEK groups were significantly improved, the levels of Aβ1-42 in the hippocampus decreased, and matrix metalloproteinase-9 (MMP-9) levels increased compared with the untreated group. Here, MMP9 is linked to Alzheimer disease.